Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer

BACKGROUND: Docetaxel improves symptoms and survival in metastatic castration-resistant prostate cancer (CRPC). However, ∼50% of patients are chemoresistant. This study examined whether changes in cytokine levels predict for docetaxel resistance in vitro and in a clinical cohort. METHODS: PC3 cells...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahon, K L, Lin, H-M, Castillo, L, Lee, B Y, Lee-Ng, M, Chatfield, M D, Chiam, K, Breit, S N, Brown, D A, Molloy, M P, Marx, G M, Pavlakis, N, Boyer, M J, Stockler, M R, Daly, R J, Henshall, S M, Horvath, L G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4402456/
https://www.ncbi.nlm.nih.gov/pubmed/25867259
http://dx.doi.org/10.1038/bjc.2015.74

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4402456/
https://www.ncbi.nlm.nih.gov/pubmed/25867259
http://dx.doi.org/10.1038/bjc.2015.74

Ejemplares similares